NRX Pharmaceuticals (NRXP) Other Non-Current Liabilities (2021 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Other Non-Current Liabilities of $8.8 million for Q1 2026, down 11.02% year-over-year from $9.9 million in Q1 2025, and down 28.75% quarter-over-quarter from $12.3 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Other Non-Current Liabilities for 5 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 11.02% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $8.8 million (down 11.02% YoY), while the FY2025 annual figure was $12.3 million, up 118.19% from the prior year.
- Other Non-Current Liabilities eased to $8.8 million in Q1 2026 per NRXP's latest filing, from $12.3 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $16.3 million in Q2 2025 and bottomed at $8000.0 in Q2 2024.
- Historically, Other Non-Current Liabilities has averaged $7.8 million across 4 years, with a median of $8.8 million in 2026.
- Annual changes were most pronounced in 2025 — Other Non-Current Liabilities surged 203225.0% — and 2026, when it dropped 11.02%.
- NRX Pharmaceuticals' Other Non-Current Liabilities stood at $17000.0 in 2023, then surged by 33070.59% to $5.6 million in 2024, then soared by 118.19% to $12.3 million in 2025, then declined by 28.75% to $8.8 million in 2026.
- Business Quant data shows NRXP's Other Non-Current Liabilities at $8.8 million in Q1 2026, $12.3 million in Q4 2025, and $15.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.77 Mn |
| Dec 31, 2025 | 12.30 Mn |
| Sep 30, 2025 | 15.86 Mn |
| Jun 30, 2025 | 16.27 Mn |
| Mar 31, 2025 | 9.85 Mn |
| Dec 31, 2024 | 5.64 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 8,000.00 |
| Dec 31, 2023 | 17,000.00 |
| Dec 31, 2021 | -1.10 Mn |
| Sep 30, 2021 | -1.10 Mn |
| Jun 30, 2021 | -1.10 Mn |